3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
Three-dimensional quantitative structure-activity relationship (3D-QSAR) models were constructed using comparative molecular field analysis (CoMFA) for a series of delta opioid receptor agonists: SNC80 analogs. Quantum chemical calculations on SNC80 show that protonation is preferred at the basic N4 atom over the alternative N1 atom, accordingly N4 protonation may contribute significantly to ligand-receptor interactions under physiologically relevant conditions. Statistically significant and predictive CoMFA models were achieved by pooling biological data from independent published sources, including compounds with both alphaR and alphaS benzylic configurations. Improved CoMFA models were obtained when the compounds were considered as N4-protonated species rather than neutral compounds. The influence of various atomic partial-charge formalisms, alignment schemes and additional molecular descriptors was evaluated in order to produce the highest quality models. In addition, separate CoMFA models were generated for compounds with only the alphaR benzylic configuration. These CoMFA models showed excellent internal predictability and consistency, and external validation using test-set compounds yielded predicted pIC50 values within 1log unit of the corresponding experimentally measured values. Key insights into the structure-activity relationship derived from the CoMFA analysis concur with experimentally observed data, thus the CoMFA models presented here find utility for predicting the binding affinity, and guiding the design, of novel SNC80 analogs and related delta opioid receptor agonists.
Peng
Youyi
Y
Department of Pharmacology, University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical School (UMDNJ-RWJMS), and the Informatics Institute of UMDNJ, Piscataway, NJ 08854, USA.
Keenan
Susan M
SM
Zhang
Qiang
Q
Welsh
William J
WJ
D000818:Animals; D001549:Benzamides / Q000737:chemistry* / Q000378:metabolism; D001665:Binding Sites; D008956:Models, Chemical; D008958:Models, Molecular; D008968:Molecular Conformation; D010879:Piperazines / Q000737:chemistry* / Q000378:metabolism; D011522:Protons; D021281:Quantitative Structure-Activity Relationship; D051381:Rats; D017465:Receptors, Opioid, delta / Q000819:agonists* / Q000737:chemistry* / Q000378:metabolism; D013816:Thermodynamics
D001549:Benzamides; D010879:Piperazines; D011522:Protons; D017465:Receptors, Opioid, delta; C088464:4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide